REFERENCES

1. Ko JP, Berman EJ, Kaur M, et al. Pulmonary Nodules: growth rate assessment in patients by using serial CT and three-dimensional volumetry. Radiology 2012;262:662-71.

2. Henschke CI, Yankelevitz DF, Yip R, et al. Writing Committee for the I-ELCAP Investigators. Lung cancers diagnosed at annual CT screening: volume doubling times. Radiology 2012;263:578-83.

3. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000;73:1252-9.

4. Wilson DO, Ryan A, Fuhrman C, et al. Doubling times and CT screen-detected lung cancers in the Pittsburgh Lung Screening Study. Am J Respir Crit Care Med 2012;185:85-9.

5. Jennings SG, Winer-Muram HT, Tann M, Ying J, Dowdeswell I. Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements. Radiology 2006;241:554-63.

6. Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002;223:798-805.

7. Sala E, Mema E, Himoto Y, et al. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol 2017;72:3-10.

8. Yang F, Wang Y, Li Q, et al. Intratumor heterogeneity predicts metastasis of triple-negative breast cancer. Carcinogenesis 2017;38:900-9.

9. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.

10. Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med 2018;50:e416.

11. Morris LG, Riaz N, Desrichard A, et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 2016;7:10051-63.

12. Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics. J Nucl Med 2020;61:488-95.

13. Benoit-Cattin H. Texture analysis for magnetic resonance imaging. Available from: https://books.google.com.hk/books?hl=zh-CN&lr=&id=kNFKek4RtnkC&oi=fnd&pg=PA9&dq=Texture+Analysis+for+Magnetic+Resonance+Imaging&ots=PGtzjqs0Sy&sig=cQPfAbJy7KIqWCXJEijzRLabik4&redir_esc=y#v=onepage&q=Texture%20Analysis%20for%20Magnetic%20Resonance%20Imaging&f=false [Last accessed on 21 Mar 2022].

14. Laine A, Fan J. Texture classification by wavelet packet signatures. IEEE Trans Pattern Anal Machine Intell 1993;15:1186-91.

15. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.

16. Wilson R, Devaraj A. Radiomics of pulmonary nodules and lung cancer. Transl Lung Cancer Res 2017;6:86-91.

17. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016;278:563-77.

18. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-6.

19. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45.

20. Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med 2011;52:1690-7.

21. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.

22. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-34.

23. Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging 2013;40:133-40.

24. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013;108:479-85.

25. Petkovska I, Shah SK, McNitt-Gray MF, et al. Pulmonary nodule characterization: a comparison of conventional with quantitative and visual semi-quantitative analyses using contrast enhancement maps. Eur J Radiol 2006;59:244-52.

26. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J 2013;42:1659-67.

27. Hawkins S, Wang H, Liu Y, et al. Predicting malignant nodules from screening CT scans. J Thorac Oncol 2016;11:2120-8.

28. Lee SH, Lee SM, Goo JM, Kim KG, Kim YJ, Park CM. Usefulness of texture analysis in differentiating transient from persistent part-solid nodules(PSNs): a retrospective study. PLoS One 2014;9:e85167.

29. Kido S, Kuriyama K, Higashiyama M, Kasugai T, Kuroda C. Fractal analysis of small peripheral pulmonary nodules in thin-section CT: evaluation of the lung-nodule interfaces. J Comput Assist Tomogr 2002;26:573-8.

30. Liu Y, Kim J, Balagurunathan Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer 2016;17:441-8.e6.

31. Weiss GJ, Ganeshan B, Miles KA, et al. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS One 2014;9:e100244.

32. Yip SS, Kim J, Coroller TP, et al. Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung cancer. J Nucl Med 2017;58:569-76.

33. Maldonado F, Boland JM, Raghunath S, et al. Noninvasive characterization of the histopathologic features of pulmonary nodules of the lung adenocarcinoma spectrum using computer-aided nodule assessment and risk yield (CANARY)--a pilot study. J Thorac Oncol 2013;8:452-60.

34. Dong X, Xing L, Wu P, et al. Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma: relationship between tumor 18F-fluorodeoxyglucose uptake heterogeneity, maximum standardized uptake value, and tumor stage. Nucl Med Commun 2013;34:40-6.

35. Yang F, Thomas MA, Dehdashti F, Grigsby PW. Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer. Eur J Nucl Med Mol Imaging 2013;40:716-27.

36. Cook GJ, Yip C, Siddique M, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 2013;54:19-26.

37. Coroller TP, Agrawal V, Narayan V, et al. Radiomic phenotype features predict pathological response in non-small cell lung cancer. Radiother Oncol 2016;119:480-6.

38. Wang T, Deng J, She Y, et al. Radiomics signature predicts the recurrence-free survival in stage I non-small cell lung cancer. Ann Thorac Surg 2020;109:1741-9.

39. Papp L, Rausch I, Grahovac M, Hacker M, Beyer T. Optimized feature extraction for radiomics analysis of ¹⁸F-FDG PET imaging. J Nucl Med 2019;60:864-72.

40. Lasnon C, Majdoub M, Lavigne B, et al. ¹⁸F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. Eur J Nucl Med Mol Imaging 2016;43:2324-35.

41. Pavic M, Bogowicz M, Würms X, et al. Influence of inter-observer delineation variability on radiomics stability in different tumor sites. Acta Oncol 2018;57:1070-4.

42. da Silva GLF, Valente TLA, Silva AC, de Paiva AC, Gattass M. Convolutional neural network-based PSO for lung nodule false positive reduction on CT images. Comput Methods Programs Biomed 2018;162:109-18.

43. Paul R, Hawkins SH, Balagurunathan Y, et al. Deep feature transfer learning in combination with traditional features predicts survival among patients with lung adenocarcinoma. Tomography 2016;2:388-95.

44. Avanzo M, Stancanello J, Pirrone G, Sartor G. Radiomics and deep learning in lung cancer. Strahlenther Onkol 2020;196:879-87.

45. Koike T, Yamato Y, Yoshiya K, Shimoyama T, Suzuki R. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg 2003;125:924-8.

46. Keenan RJ, Landreneau RJ, Maley RH Jr, et al. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg 2004;78:228-33; discussion 228-33.

47. Harada H, Okada M, Sakamoto T, Matsuoka H, Tsubota N. Functional advantage after radical segmentectomy versus lobectomy for lung cancer. Ann Thorac Surg 2005;80:2041-5.

48. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 2005;129:87-93.

49. Yoshida J, Nagai K, Yokose T, et al. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg 2005;129:991-6.

50. Altorki NK, Yip R, Hanaoka T, et al. I-ELCAP Investigators. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg 2014;147:754-62; Discussion 762-4.

51. Dziedzic R, Zurek W, Marjanski T, et al. Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg 2017;52:363-9.

52. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: a review of SEER data. Chest 2011;139:491-6.

53. Wisnivesky JP, Henschke CI, Swanson S, et al. Limited resection for the treatment of patients with stage IA lung cancer. Ann Surg 2010;251:550-4.

54. Sadeghi AH, Maat APWM, Taverne YJHJ, et al. Virtual reality and artificial intelligence for 3-dimensional planning of lung segmentectomies. JTCVS Tech 2021;7:309-21.

55. Iizuka S, Kuroda H, Yoshimura K, et al. Predictors of indocyanine green visualization during fluorescence imaging for segmental plane formation in thoracoscopic anatomical segmentectomy. J Thorac Dis 2016;8:985-91.